131 related articles for article (PubMed ID: 18464243)
1. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities.
Haruta M; Arai Y; Sugawara W; Watanabe N; Honda S; Ohshima J; Soejima H; Nakadate H; Okita H; Hata J; Fukuzawa M; Kaneko Y
Genes Chromosomes Cancer; 2008 Aug; 47(8):712-27. PubMed ID: 18464243
[TBL] [Abstract][Full Text] [Related]
2. Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children.
Haruta M; Arai Y; Watanabe N; Fujiwara Y; Honda S; Ohshima J; Kasai F; Nakadate H; Horie H; Okita H; Hata J; Fukuzawa M; Kaneko Y
Cancer Sci; 2012 Jun; 103(6):1129-35. PubMed ID: 22409817
[TBL] [Abstract][Full Text] [Related]
3. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
Wang WH; Duan JX; Vu TH; Hoffman AR
J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
[TBL] [Abstract][Full Text] [Related]
5. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Brown KW; Power F; Moore B; Charles AK; Malik KT
Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
[TBL] [Abstract][Full Text] [Related]
6. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
7. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
8. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
Mummert SK; Lobanenkov VA; Feinberg AP
Genes Chromosomes Cancer; 2005 Jun; 43(2):155-61. PubMed ID: 15761865
[TBL] [Abstract][Full Text] [Related]
9. Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting.
Dao D; Walsh CP; Yuan L; Gorelov D; Feng L; Hensle T; Nisen P; Yamashiro DJ; Bestor TH; Tycko B
Hum Mol Genet; 1999 Jul; 8(7):1337-52. PubMed ID: 10369881
[TBL] [Abstract][Full Text] [Related]
10. Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor.
Malik K; Salpekar A; Hancock A; Moorwood K; Jackson S; Charles A; Brown KW
Cancer Res; 2000 May; 60(9):2356-60. PubMed ID: 10811108
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors.
Bjornsson HT; Brown LJ; Fallin MD; Rongione MA; Bibikova M; Wickham E; Fan JB; Feinberg AP
J Natl Cancer Inst; 2007 Aug; 99(16):1270-3. PubMed ID: 17686827
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
[TBL] [Abstract][Full Text] [Related]
14. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor.
Taniguchi T; Sullivan MJ; Ogawa O; Reeve AE
Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2159-63. PubMed ID: 7534414
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15.
Brandt A; Löhers K; Beier M; Leube B; de Torres C; Mora J; Arora P; Jat PS; Royer-Pokora B
PLoS One; 2016; 11(5):e0155561. PubMed ID: 27213811
[TBL] [Abstract][Full Text] [Related]
17. Genomic imprinting and Wilms' tumor.
Moulton T; Chung WY; Yuan L; Hensle T; Waber P; Nisen P; Tycko B
Med Pediatr Oncol; 1996 Nov; 27(5):476-83. PubMed ID: 8827077
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of imprinted genes in Wilms tumors.
Hubertus J; Lacher M; Rottenkolber M; Müller-Höcker J; Berger M; Stehr M; von Schweinitz D; Kappler R
Oncol Rep; 2011 Mar; 25(3):817-23. PubMed ID: 21174059
[TBL] [Abstract][Full Text] [Related]
19. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor.
Ravenel JD; Broman KW; Perlman EJ; Niemitz EL; Jayawardena TM; Bell DW; Haber DA; Uejima H; Feinberg AP
J Natl Cancer Inst; 2001 Nov; 93(22):1698-703. PubMed ID: 11717330
[TBL] [Abstract][Full Text] [Related]
20. Stratification of Wilms tumor by genetic and epigenetic analysis.
Scott RH; Murray A; Baskcomb L; Turnbull C; Loveday C; Al-Saadi R; Williams R; Breatnach F; Gerrard M; Hale J; Kohler J; Lapunzina P; Levitt GA; Picton S; Pizer B; Ronghe MD; Traunecker H; Williams D; Kelsey A; Vujanic GM; Sebire NJ; Grundy P; Stiller CA; Pritchard-Jones K; Douglas J; Rahman N
Oncotarget; 2012 Mar; 3(3):327-35. PubMed ID: 22470196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
